ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

Mylan Confirms Endo Suit Over Generic Migraine Drug Application

DOW JONES NEWSWIRES Mylan Inc. (MYL) confirmed Wednesday that it has been sued by Endo Pharmaceuticals Holdings Inc. (ENDP) over its application for approval of a generic drug used to treat acute migraine headaches in adults. Mylan--one of the world's largest generic drug makers--said it believes it is the first company to file a substantially complete application for approval of frovatriptan succinate EQ, a generic version of Frova. The company said it expects to qualify for 180 days of marketing exclusivity upon final approval from the Food and Drug Administration. Mylan, which has had litigation-related charges figure prominently in its recent quarterly results, last month reported second-quarter earnings surged 70% as sales got a lift from a weaker dollar. Shares closed Tuesday at $20.01 and were inactive in recent premarket trade. Through the latest close, the stock is down 5.3% since the start of the year. -By Mia Lamar, Dow Jones Newswires; 212-416-3207;

Stock News for Mylan Inc. (MYL)
07/29/201508:30:05Mylan Gets European Regulator's Approval for Perrigo Deal
07/29/201507:00:00Mylan Announces Receipt of Unconditional Clearance from European...
07/28/201506:51:14Proxy Statement - Merger or Acquistion (definitive) (defm14a)
07/27/201517:10:14Mylan's Leverage to Resist Teva Deal Reveals Shift in Rules
07/27/201516:56:51Current Report Filing (8-k)
07/27/201516:53:53Current Report Filing (8-k)
07/27/201515:58:00Mylan Announces Meeting Date and Record Date of Extraordinary...
07/27/201510:11:55Teva to Buy Allergan Generics for $40.5 Billion -- 7th Update
07/27/201509:01:32Teva to Buy Allergan Generics for $40.5 Billion -- 6th Update
07/27/201508:35:11Teva to Buy Allergan Generics for $40.5 Billion -- 5th Update
07/27/201506:42:00Mylan Comments on Teva's Agreement to Acquire Allergan's Generic...
07/27/201506:30:03Teva to Buy Allergan Generics for $40.5 Billion
07/25/201521:13:05Teva in Talks to Buy Allergan's Generics Unit -- 4th Update
07/24/201515:28:00Mylan Schedules Second Quarter 2015 Financial Results Conference...
07/24/201511:00:00Proxy Soliciting Materials (revised) (prer14a)
07/23/201517:19:34Current Report Filing (8-k)
07/23/201517:17:50Additional Proxy Soliciting Materials (definitive) (defa14a)
07/23/201512:20:06Drugmaker Mylan Uses Dutch Foundation to Fend Off Hostile Bid
07/23/201508:47:00Mylan Acknowledges Exercise of Full Call Option by the Independent...
07/22/201510:00:07Abbott Labs Profit Beats Expectations

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations